Pipeline-focused public companies
Find biotechnology and pharmaceutical companies by market profile and drug-development maturity, then open each ticker for its stock, pipeline and catalyst research page.
| Company | Price | Market cap | Pipeline | Next catalyst | Open |
|---|---|---|---|---|---|
| PA PASGPassage Bio | $4.44-0.9% | $14.3M | 2 assetsStage unavailable | No dated catalyst | |
| PB PBLSParbaillis Medicines | $39.36-0.6% | $4.86B | 3 assetsPhase 1/2 | Zolucatetide (FOG-001)Phase 1/2 · Data readout | |
The screener is the parent research index for individual ticker pages such as CAPR. Filter the biotech company universe here, then open a company to review its stock snapshot, drug assets, clinical stage and dated catalysts. Quote information is a cached market snapshot and may be delayed.
| $9.24+1.4% |
| $477.0M |
13 assetsPhase 2 |
AlisertibPhase 2 · Data readout |
| PC PCRXPacira BioSciences | $24.67+3.5% | $983.4M | 7 assetsPhase 3 | PCRX-201 (enekinragene inzadenovec)Phase 2 · Data readout |
| PC PCSAProcessa Pharmaceuticals | $2.08-3.0% | $5.8M | 6 assetsStage unavailable | No dated catalyst |
| PC PCVXVaxcyte | $62.62+2.1% | $9.32B | 4 assetsPhase 3 | VAX-31Phase 3 · Data readout |
| PD PDSBPDS Biotech | $0.22+4.6% | $12.2M | 12 assetsStage unavailable | No dated catalyst |
| PE PEPGPepGen | $3.14+3.5% | $217.2M | 2 assetsPhase 2 | PGN-EDODM1Phase 2 · Data readout |
| PF PFEPfizer | $28.07+1.0% | $159.99B | 61 assetsPDUFA | Talzenna/Talazoparib + Xtandi/Enzalutamide (BMN 673 + MDV3100) (PARP Inhibitor)PDUFA · Approval decision |
| PG PGENPrecigen | $7.20-3.2% | $2.58B | 7 assetsStage unavailable | No dated catalyst |
| PH PHARPharming Group | $11.85+1.5% | $838.7M | 5 assetsPDUFA | LeniolisibPDUFA · Approval decision |
| PH PHATPhathom Pharmaceuticals | $8.87+3.1% | $717.6M | 5 assetsPhase 2 | VOQUEZNA® (Vonoprazan)(potassium competitive acid blocker)Phase 2 · Data readout |
| PH PHGEBiomX | $0.14-1.6% | $3.7M | 2 assetsStage unavailable | No dated catalyst |
| PH PHIOPhio Pharmaceuticals | $1.18-2.5% | $13.7M | 3 assetsStage unavailable | No dated catalyst |
| PH PHVSPharvaris B.V. | $36.27-0.3% | $2.55B | 4 assetsPhase 3 | Deucrictibant immediate-release capsules (PHVS416)Phase 3 · Data readout |
| PI PIRSPieris Pharmaceuticals | $13.60-15.7% | — | 4 assetsStage unavailable | No dated catalyst |
| PL PLRXPliant Therapeutics | $1.16+3.1% | $71.5M | 5 assetsPhase 1b | PLN-101095Phase 1b · Data readout |
| PL PLURPluri Inc. | $1.71-2.8% | $18.5M | 5 assetsStage unavailable | No dated catalyst |
| PL PLXProtalix Biotherapeutics | $2.38+0.0% | $191.8M | 6 assetsPhase 2 | PRX-115Phase 2 · Data readout |
| PL PLXPPLx Pharma Inc | $0.00+0.0% | — | 1 assetsStage unavailable | No dated catalyst |
| PM PMNProMIS Neurosciences | $14.51-2.7% | $130.1M | 3 assetsPhase 1b | PMN310Phase 1b · Data readout |
| PM PMVPPMV Pharma | $1.33+2.3% | $71.1M | 3 assetsStage unavailable | No dated catalyst |
| PP PPBTPurple Biotech Ltd | $1.57-0.6% | $2.6M | 4 assetsStage unavailable | No dated catalyst |
| PR PRAXPraxis Precision Medicines | $375.94+3.1% | $10.50B | 8 assetsPDUFA | Relutrigine (PRAX-562)PDUFA · Approval decision |
| PR PRLDPrelude Therapeutics Incorporated | $6.63+2.0% | $529.1M | 11 assetsStage unavailable | No dated catalyst |
| PR PRMEPrime Medicine | $3.39+4.6% | $614.9M | 3 assetsStage unavailable | No dated catalyst |
| PR PROKProKidney | $1.61+13.4% | $642.7M | 2 assetsPhase 3 | Rilparencel (REACT®)Phase 3 · Data readout |
| PR PRQRProQR | $2.34+3.1% | $330.2M | 9 assetsPhase 1 | AX-0810Phase 1 · Data readout |
| PR PRTAProthena Corporation | $9.45+4.7% | $485.1M | 7 assetsPhase 3 | BMS-986446 (PRX005)Phase 2 · Data readout |
| PR PRTKParatek Pharmaceuticals | $2.23+0.0% | — | 4 assetsStage unavailable | No dated catalyst |
| PS PSNLPersonalis | $18.38+8.9% | $1.96B | 3 assetsStage unavailable | No dated catalyst |
| PS PSTXPoseida Therapeutics | $9.50+0.0% | — | 4 assetsStage unavailable | No dated catalyst |
| PT PTCTPTC Therapeutics | $69.82-1.0% | $5.83B | 11 assetsStage unavailable | No dated catalyst |
| PT PTGXProtagonist Therapeutics | $154.32+2.4% | $9.99B | 14 assetsApproved | Rusfertide (PTG-300) PDUFA · Approval decision |
| PT PTHSPelthos Therapeutics | $25.51-4.3% | $97.7M | 4 assetsPhase 1/2 | CT2000 (NaV1.7 Inhibitor)Phase 1/2 · Data readout |
| PT PTIXProtagenic Therapeutics | $0.80+33.5% | $1.4M | 1 assetsStage unavailable | No dated catalyst |
| PT PTNPalatin Technologies | $9.69-7.2% | $17.2M | 10 assetsPhase 2 | Bremelanotide + PDE5iPhase 2 · Data readout |
| PV PVLAPalvella Therapeutics | $142.04-0.4% | $2.05B | 4 assetsPhase 2 | QTORIN Rapamycin Phase 2 · Data readout |
| PY PYPDPolypid | $5.10+0.4% | $103.6M | 1 assetsPDUFA | D-PLEX-100PDUFA · Approval decision |
| PY PYXSPyxis Oncology | $3.08-1.3% | $256.9M | 3 assetsPhase 1/2 | Micvotabart pelidotin (MICVO, formerly PYX-201)Phase 1 · Data readout |